SCHEMBL4741832

SCHEMBL4741832

CC(C)(C)c1ccc(Cn2c(-c3c(Br)cccc3Br)nc(O)cc2=O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR9 P51686 10/20 0.44
EGLN3 Q9H6Z9 1/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
TP53 P04637 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
FBP1 P09467 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
METAP2 P50579 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4739209 0.88 EGLN3 (0.46) CCR9EGLN3MEN1KMT2ATP53
SCHEMBL4739127 0.88 KMT2A (0.44) CCR9EGLN3MEN1KMT2ATP53
SCHEMBL4739981 0.87 EGLN3 (0.56) CCR9EGLN3MEN1KMT2ATP53
SCHEMBL4737534 0.86 EGLN3 (0.44) CCR9EGLN3MEN1KMT2ATP53
SCHEMBL4782916 0.84 CCR9 (0.43) CCR9EGLN3MEN1KMT2ATP53
SCHEMBL4741831 0.84 EGLN3 (0.48) CCR9EGLN3MEN1KMT2AKDM4E
SCHEMBL4740088 0.83 CCR9 (0.45) CCR9EGLN3MEN1KMT2ATP53
SCHEMBL5000326 0.82 CCR9 (0.47) CCR9EGLN3MEN1KMT2ATP53
SCHEMBL4740335 0.82 EGLN3 (0.46) CCR9EGLN3MEN1KMT2AKDM4E
SCHEMBL4737518 0.81 EGLN3 (0.51) CCR9EGLN3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 CCR9 4560/4885EGLN3 3/4885MEN1 2935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.